Related Experiment Video
Updated: Jun 29, 2026
14:45
Analyzing the Parkinson's Disease Mouse Model Induced by Adeno-associated Viral Vectors Encoding Human α-Synuclein
Published on: July 29, 2022
alpha-Synuclein: a therapeutic target for Parkinson's disease?
1Department of Neuroscience, Georgetown University Medical Center, 3970 Reservoir Road, Washington, DC 20057, United States. km445@georgetown.edu
Pharmacological Research
|October 9, 2008
Summary
Parkinson's disease involves dopamine neuron loss and motor symptoms. Targeting toxic alpha-synuclein conformers offers a new therapeutic strategy to potentially slow disease progression.
Area of Science:
- Neuroscience
- Neurology
- Pathology
Background:
- Parkinson's disease (PD) is a progressive neurodegenerative disorder characterized by dopamine neuron loss in the substantia nigra.
- Motor symptoms like tremor and rigidity are hallmarks, but PD is increasingly recognized as a multisystem disorder affecting peripheral and extra-nigral systems.
- The exact cause of sporadic PD remains unknown, yet misfolded alpha-synuclein is implicated in familial forms and animal models.
Purpose of the Study:
- To review the role of alpha-synuclein in Parkinson's disease pathogenesis.
- To explore toxic alpha-synuclein conformers as potential therapeutic targets.
Main Methods:
- Literature review focusing on alpha-synuclein's role in PD.
- Analysis of current therapeutic strategies and their limitations.
- Evaluation of novel therapeutic approaches targeting specific protein conformations.
Main Results:
- Misfolded alpha-synuclein, particularly toxic conformers, is central to PD pathogenesis.
- Current therapies primarily manage motor symptoms by boosting dopamine, without addressing underlying pathology.
- Targeting protofibrillar/oligomeric forms of alpha-synuclein shows promise.
Conclusions:
- Alpha-synuclein is a critical factor in Parkinson's disease.
- Developing neurotherapeutics aimed at toxic alpha-synuclein conformers could offer a novel treatment strategy.
- Such therapies may extend the symptom-free period and mitigate disease pathogenesis.
More Related Videos
Related Concept Videos
01:24Parkinson Disease ll: Pathophysiology
Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
01:24Parkinson Disease l: Introduction
Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of which...
01:15Parkinson's Disease: Overview
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
01:24Parkinson's Disease: Treatment
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
01:37Neural Regulation
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...